Context: Although age-related declines in dehydroepiandrosterone sulfate (DHEAS) and testosterone are associated with cardiovascular risk, it remains to be determined whether replacement of these hormones improves cardiovascular risk factors.
both men and women with advancing age (5) . Based mainly on data from observational studies in humans (1, 2) and experiments in animals (3, 4) , DHEA has been marketed as an "antiaging" supplement claimed to protect against CVD and other chronic illness. Being a sex steroid precursor hormone, DHEA is thought to influence lipid metabolism and thereby CVD risk (6) . Similar to DHEA, testosterone also declines with age in men (7) . Cross-sectional studies have also suggested that low levels of bioavailable testosterone may lead to increased risk of coronary artery disease (CAD) in men (8, 9) . In particular, testosterone deficiency has been shown to increase the atherogenic potential of lipoprotein particles (7) . Therefore, we hypothesized that DHEA replacement in healthy elderly men and women, as well as testosterone replacement in healthy elderly men, would result in improvements in the lipid and lipoprotein profile.
There is growing evidence indicating that lipoprotein particle size plays a role in mitigating CVD risk, with large low-density lipoprotein (LDL) and large high-density lipoprotein (HDL) particles associated with reductions in CVD risk (10, 11) . For example, families with exceptional longevity have been shown to have larger LDL and HDL particle sizes, irrespective of their total concentrations of lipids and apolipoproteins (12) . Moreover, there is also an inverse relationship between CVD risk factors and LDL and HDL particle sizes (12, 13) . Although the clinical utility is not fully established, lipoprotein particle sizes and concentrations assessed by nuclear magnetic resonance (NMR) have been shown to be superior to traditional lipid measures in predicting CVD risk (14) .
Lipoprotein particles have been shown to exhibit ageand sex-related characteristics (15) . It is known that females have less atherogenic lipoprotein profile compared with males (e.g. higher HDL concentrations) (15, 16) . Irrespective of sex, lipoprotein particle sizes undergo undesired changes with age (17) , specifically increasing their atherogenic potential. Whether replacement of DHEA or testosterone has any effect on reversing these age-related changes in lipoprotein particle profile is unknown. Due to the widespread use of these hormones, it is important to address the effectiveness and safety of DHEA or testosterone replacement in improving cardiovascular health on a long-term basis (18) .
Hence, the aim of the current study was: 1) to assess the impact of age and sex on lipoprotein particle concentration and size as assessed by NMR; and 2) to evaluate the role of DHEA or low-dose testosterone replacement for 2 yr in elderly men with low DHEAS and bioavailable testosterone levels and DHEA in elderly women with low DHEAS on the lipoprotein profiles, especially on LDL and HDL particle sizes and concentrations as measured by NMR.
Subjects and Methods

Subjects
The study was approved by the Mayo Clinic Institutional Review Board (Rochester, MN). A detailed description of the study design and methodology has already been described as part of another publication (19) . Briefly, this is a 2-yr randomized, double-blind, placebo-controlled study done in the absence of industry support. Potential research volunteers were recruited from the greater Rochester, Minnesota, and Olmstead county area by local radio and newspaper advertisements. Volunteers were eligible to participate in this study if they were 60 yr of age or greater and had both a DHEAS concentration less than 1.57 g/ml (4.3 mol/liter) and a bioavailable testosterone concentration of less than 103 ng/dl (3.6 nmol/liter) for elderly men and a DHEAS concentration of less than 0.95 g/ml (2.6 mol/liter) for elderly women. These cutoff values, which represented the 15th percentile of levels for normal young men and women (20) , were chosen to ensure that a sufficient number of healthy elderly people could participate in the study, as previously reported (19) . Exclusion criteria included evidence of clinically important coexisting illness or conditions. A total of 92 elderly men and 62 elderly women were randomly assigned to the study groups. Also included were 37 healthy young men and 38 healthy young women between the ages of 18 and 31 yr to obtain a baseline comparison of outcome measures. For the present subanalysis, only the participants with a complete set (baseline and 24month) of unfrozen EDTA plasma samples were included, which was necessary for the NMR lipoprotein profiling. Baseline characteristics are presented in Table 1 and have been reported previously (19) .
Experimental design
Elderly men received either a DHEA tablet (75 mg/d) plus a transdermal placebo patch; a placebo tablet plus a transdermal testosterone patch (5 mg/d, D-TRANS; Alza Corp., Mountain View, CA); or a placebo tablet plus a placebo transdermal patch. Elderly women received either DHEA (50 mg/d) or placebo. Every 3 months, participants received a new supply of tablets and patches from the Mayo Clinic's Research pharmacy and were asked to return any unused tablets or patches to monitor study compliance. Fasting blood samples were collected at baseline and every 3 months for the measurement of liver enzymes, hematocrit, testosterone, and DHEAS. In addition, fasting blood samples were collected at baseline and at 24 months for measurement of lipid and lipoprotein concentrations. For young participants only baseline blood samples were collected.
Analytic procedures
Plasma concentrations of DHEAS and total and bioavailable testosterone were measured by competitive chemiluminescence immunoassay. SHBG was measured by solid-phase, two-site chemiluminescence immunometric assay (Immulite; Diagnostic Products Corp., Los Angeles, CA). Bioavailable testosterone was measured on the basis of differential precipitation of SHBG by ammonium sulfate after the equilibration of serum samples with tracer amounts of tritium-labeled testosterone. The intraassay coefficients of variation for DHEA, total and bioavailable testosterone, and SHBG were below 7%, below 8%, below 6%, and below 5%, respectively. The interassay coefficients of variation for DHEA, total and bioavailable testosterone, and SHBG were below 12%, below 10%, below 8%, and below 6%, respectively.
The lipoprotein particle size and concentrations were measured in plasma in the Cardiovascular Medicine Laboratory at the Mayo Clinic using a 400-MHz NMR lipoprotein analyzer system developed by LipoScience Inc. (Raleigh, NC), as described previously (21) . Samples were run one or two times per week in batches of 60 -64 samples. The first few analysis batches contained a mixture of elderly male, elderly female, young male, and young female samples.
Statistical analysis
Baseline demographic characteristics are presented as the median with the interquartile range (IQR). Changes in the outcome measures were calculated by comparing the value at baseline with that taken at the last measurement. Baseline comparisons between treatment groups were conducted using a nonparametric Wilcoxon rank sum test. Nonparametric analyses were chosen in the present study because the lipoprotein particle data were not normally distributed. Multiple regression analyses were conducted to examine the treatment effects on the change in each of the outcome variables; the dependent variable was the change from baseline to 24 months (with the use of a rank transformation), and the independent variables included were the treatment group, the sex of the participant, the age of the participant at enrollment, length of follow-up, and the baseline value. Because approximately 25% of the elderly participants were taking statins (including atorvastatin, lovastatin, pravastatin, and simvastatin), statin therapy was considered as a potential covariate. However, because there was no effect of statin therapy on the change in any of the clinical outcomes in response to DHEA or testosterone, statin therapy was not included in the final model. Data maintenance, editing, and analysis were carried out in the Division of Biostatistics at the Mayo Clinic.
Results
The median duration of treatment within the DHEA, testosterone, and placebo groups in elderly men was 23.2 (22.6 to 23.5), 23.2 (22.2 to 23.8), and 23.1 (22.7 to 24.0) months, respectively. For elderly women, the median duration of treatment with DHEA and placebo was 23.0 (22.7 to 23.7) and 23.3 (22.4 to 23.5) months, respectively. In the group of elderly men, 31 of 32 subjects completed the placebo arm, 29 of 30 subjects completed the DHEA arm, and 27 of 30 subjects completed the testosterone arm in the parent study (19) . In the group of elderly women, 30 of 30 subjects completed the placebo arm, and 27 of 30 subjects completed the DHEA arm in the parent study (19) . Overall study compliance on average was above 95% for all treatments. Table 1 summarizes the baseline characteristics for the participants included in the present analysis. There were no differences noted between groups in terms of age, weight, body mass index (BMI), total body fat, ratio of visceral fat to total body fat, visceral fat, or fat free mass. However, in elderly women there were significant differences in BMI and (40).
Baseline demographics
fasting glucose at baseline between treatment groups. In addition, there were no significant differences observed between groups for DHEAS, total testosterone, bioavailable testosterone (in men), fasting insulin, fasting glucose concentrations, or insulin sensitivity index.
Effect of DHEA or testosterone in elderly men and DHEA in elderly women on DHEA and testosterone concentrations
The changes in DHEAS, bioavailable testosterone, and total testosterone have been previously reported (19) . In brief, DHEA therapy increased the plasma levels of DHEAS by a median of 3.4 g/ml (9.2 mol/liter) in elderly men and by 3.8 g/ml (10.3 mol/liter) in elderly women. DHEAS values on therapy reached levels equivalent to that of high normal levels seen in younger adults. Treatment with DHEA increased the level of total testosterone by a median of 19.8 ng/dl (0.7 nmol/liter) in elderly women relative to placebo. In contrast, treatment with DHEA did not significantly affect total testosterone in elderly men relative to placebo. Importantly, Fig. 2 in Ref. 19 of the original publication of the results from this study demonstrates that the DHEA treatment resulted in elevations in DHEAS concentrations after 3 months of treatment and that these elevations were maintained for the duration of the study in both elderly men and elderly women. Treatment with testosterone increased the level of total testosterone by a median of 104.5 ng/dl (3.6 nmol/liter) and bioavailable testosterone by a median of 30.4 ng/dl (1.1 nmol/liter) in elderly men relative to placebo. As previously reported (22) , treatment with testosterone raised total testosterone concentrations to levels seen in young adults and also raised bioavailable testosterone by approximately 50%, which would represent a partial restoration toward levels seen in young adults. The incomplete restoration of bioavailable testosterone may be due in part to a testosterone-induced suppression of endogenous testosterone production as indicated by declines in the concentrations of both LH and FSH relative to placebo (Ϫ1.8 IU/liter and 3.0 IU/liter, respectively) (19) . Figure 2 from the original publication of the results from this study (19) also demonstrates that testosterone treatment resulted in elevations in bioavailable testosterone after approximately 6 -9 months of treatment and that these elevations were maintained for the duration of the study in elderly men.
Baseline lipoprotein particle sizes and concentrations
The baseline values for all LDL and HDL lipoprotein particle concentrations and sizes are summarized in Tables 2 and 3, respectively. No major differences in lipoprotein Data are expressed as median (interquartile range). No significant differences were observed between treatment groups at baseline. size or concentration were noted (P Ͼ 0.05) between treatment groups at baseline within the elderly men. However, at baseline the elderly women in the placebo treatment group had higher triglyceride concentrations than the DHEA group [median (IQR), 107 mg/dl (87,135) vs. 87 mg/dl (67,113); P ϭ 0.026]. Figure 1 shows the effect of age and sex on total cholesterol, triglyceride, LDL cholesterol, HDL cholesterol, and LDL and HDL particle concentrations. Both elderly men and women had higher total cholesterol (P Ͻ 0.001) and triglyceride (P Ͻ 0.05) concentrations compared with their younger counterparts. With regard to LDL, the elderly group had elevated LDL cholesterol (P ϭ 0.001), total LDL particle (P Ͻ 0.001), and small, dense LDL particle concentrations (P Ͻ 0.001). Total HDL cholesterol, total HDL particle, and large HDL particle concentrations were higher in women compared with men (P Ͻ 0.001). The large HDL particles were lower in both elderly men (P ϭ 0.04) and elderly women (P ϭ 0.03) than their younger counterparts. Table 3 summarizes the treatment effect with DHEA compared with placebo in elderly women and DHEA or testosterone compared with placebo in elderly men on lipoprotein particle size and numbers. Two years of treatment with DHEA in elderly women significantly reduced total HDL cholesterol concentrations (P ϭ 0.002), total HDL particle concentrations (P ϭ 0.004), and large HDL particle concentrations (P ϭ 0.003) relative to placebo. In contrast, DHEA replacement did not alter the LDL particle profile in elderly women. Two years of treatment with either DHEA or testosterone in elderly men did not significantly affect the LDL or HDL particle profiles (P Ͼ 0.05).
Effect of age and sex on lipoprotein particle sizes and concentrations
Effect of DHEA or testosterone in elderly men and DHEA in elderly women on lipoprotein particle sizes and concentrations
Discussion
The main findings from the current study are: 1) elderly men and women had higher atherogenic potential of their lipoprotein particle profiles than their younger counterparts; 2) 2 yr of DHEA replacement resulted in reductions of HDL cholesterol, total HDL particle, and large HDL particle concentrations in elderly women; 3) 2 yr of either DHEA or testosterone replacement had no measurable affect on the lipoprotein particle profiles in elderly men, despite significantly increasing DHEAS and testosterone concentrations, respectively, to levels found in young men.
The current study supports previous data suggesting that an individual's sex influences his/her lipoprotein profile. Specifically, the present data demonstrated that women had significantly higher concentrations compared with men of total HDL cholesterol, total HDL particles, and large HDL particles (Fig. 1 ). This may be related to differences in sex hormone profiles (15, 16) . In addition, there were also measurable effects of age on the lipoprotein particle profiles in both sexes as shown previously (15) . Both elderly men and women had higher total cho- lesterol and triglycerides compared with their younger counterparts. With advancing age, the concentrations of atherogenic small, dense LDL particles increased substantially in men, thus indicating a higher risk for coronary artery disease (15) . We observed that DHEA replacement in elderly men had no measurable affect on the lipoprotein profiles, whereas DHEA replacement significantly altered the HDL lipoprotein profiles in elderly women. Specifically, DHEA significantly reduced HDL cholesterol, total HDL particle, and large HDL particle concentrations in elderly women. These results are consistent with previous reports that indicate that exogenous DHEA administration results in reductions in HDL cholesterol in women (23) (24) (25) . Sim-ilarly, we also recently reported that short-term (3 months) DHEA supplementation (50 mg/d) in hypoadrenal women (characterized by absolute deficiency of DHEA) results in reductions in the large HDL particle concentration (26) . It remains uncertain why the lowering of HDL cholesterol, total HDL particle, and large HDL particle concentrations occurs in response to DHEA replacement in elderly women, but not elderly men. However, these lipid alterations may have been mediated by the DHEA-induced elevation in total testosterone that was observed among the elderly women receiving DHEA. The potential clinical implications that the DHEA-induced lowering of HDL cholesterol, total HDL particle, and large HDL particle concentrations have on CVD outcomes among elderly women remain to be fully understood.
CVD, in particular CAD, is the leading cause of morbidity and mortality among adults in the United States, and its incidence is increasing in women and with age (27) . Lipoprotein particle sizes as estimated by NMR spectroscopy have recently emerged as an important tool in the risk stratification for CAD (14) . Females generally have a less atherogenic lipoprotein profile compared with males (15, 16) . However, independent of sex, lipoprotein particles undergo several distinct modifications with age that make them more susceptible to oxidation (28, 29) , thereby increasing CAD risk in both sexes. Moreover, substantial evidence is emerging about the relationship between lipoprotein particle sizes and longevity. In a study involving Ashkenazi Jewish centenarians and their offspring, it has been reported that lower levels of small LDL particles were associated with better cardiovascular health and longevity (12) . Concentrations of large HDL and large LDL particles were significantly higher in individuals with exceptional longevity (13) and had an inverse relationship with CVD risk factors. It therefore is a concern that DHEA replacement resulted in an unfavorable effect on lipoprotein particles in women.
In randomized trials, short-term (3-6 months) replacement of DHEA has been shown to enhance cardiometa- bolic parameters by improving insulin sensitivity and reducing visceral adiposity (30, 31) . Therefore, it could be argued that these beneficial effects of DHEA replacement on insulin sensitivity and visceral adiposity outweigh the negative effects of DHEA on the lipoprotein particle profile. However, these beneficial effects on insulin sensitivity and visceral adiposity have not been shown to be sustained over longer periods (2 yr) of treatment (19) . Specifically, we have previously reported from this same cohort that 2 yr of DHEA replacement had no measurable effects on either insulin sensitivity or visceral adiposity (19) .
It is known that serum concentrations of testosterone decline with age in elderly men (7) , and testosterone deficiency has been shown to increase the predisposition to insulin resistance, visceral adiposity, dyslipidemia, and the metabolic syndrome (32, 33) , thereby increasing CVD risk. There is conflicting evidence regarding testosterone replacement on cardiometabolic parameters in randomized studies as indicated by a recent meta-analysis (34) . This is probably due to a difference in doses, duration, and importantly the route of administration (oral vs. im vs. transdermal) employed in different studies. Although there are number of studies that have examined the impact of testosterone replacement on lipid profile (7, 35) , data regarding the impact of testosterone on lipoprotein particle sizes and concentrations is still limited. In the current study, 2 yr of testosterone replacement had no measurable affect on the lipid and lipoprotein profile. The present findings are in contrast to previous reports that indicate that testosterone administration at supraphysiological doses decreases HDL cholesterol in healthy young and elderly adults (36 -38) . It is noteworthy that in the present study low-dose testosterone (5 mg/d) was used to minimize the risk of adverse effects like prostate enlargement and cancer, as previously reported (19) . Although a higher replacement dose (200 mg/every 2 wk) for shorter duration (3 months) has been shown to improve cardiometabolic parameters (39) , safety and efficacy for longer duration of its use remains uncertain. The route of administration (transdermal patch vs. im injection) may also play a role in mitigating the effects of testosterone on cardiometabolic parameters.
As stated previously, the present study is a subanalysis of a larger clinical trial that was initially powered to detect significant effects of long-term supplementation with DHEA in elderly men and women and testosterone in elderly men on body composition, bone mineral density, physical performance, and glucose tolerance in elderly adults with low androgen levels (19) . Therefore, an a priori power analysis was not feasible for the present outcomes. However, on the basis of the 95% confidence intervals (CIs) shown in Table 4 , it is not likely that our 
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Data are expressed as median difference (95% CI). All P values are two-sided and are based on multiple regression analysis in which the dependent variable was the change from baseline (with the use of a rank transformation) and the independent variables were the study group, sex, age at the time of randomization, length of follow-up, and baseline values.
negative findings can be attributed to the small number of subjects in the study. As we have previously reported (19) , these 95% CIs indicate that the number of participants was sufficient to establish any clinically meaningful treatment effects. For example, the 95% CI in the testosterone group for the changes in total LDL particle concentrations in elderly men ranged from Ϫ114 to 143 nmol/liter, thus ruling out reductions in the LDL particle concentrations greater than 114 nmol/liter (ϳ8% reduction) or increases in LDL particle concentrations greater than 143 nmol/liter (ϳ10% increase). If the study had enrolled more subjects, the CI would have been even narrower. Similarly, the 95% CI in the DHEA group for the changes in total LDL particle concentrations in elderly men ranged from Ϫ114 to 106 mol/liter (ϳ10% reduction to ϳ10% increase), and in elderly women ranged from Ϫ98 to 186 mol/liter (ϳ10% reduction to ϳ20% increase). Moreover, the 95% CI in the testosterone group for the changes in total HDL particle concentrations in elderly men ranged from Ϫ1 to 3 mol/liter (ϳ3% reduction to ϳ10% increase). Finally, the 95% CI in the DHEA group for the changes in total HDL particle concentrations in elderly men ranged from Ϫ3 to 3 mol/liter (ϳ8% reduction to ϳ8% increase). It should be recognized that approximately 25% of the elderly participants in the present study were taking statins at baseline. Among the elderly population in the greater Rochester, Minnesota, and Olmstead county areas, it is difficult to find people who are not treated with diet and/or therapeutic agents when their LDL cholesterol concentrations are above 100 mg/dl. However, the participants in the present study were randomly assigned to receive either of the treatments or a placebo. Importantly, adding statin therapy as a covariate had no affect on change in the individual lipoprotein particles.
In summary, both in elderly men and women, DHEA replacement increased the plasma levels of DHEAS to levels typically observed in younger adults. Long-term (2 yr) DHEA replacement in elderly women resulted in a lowering of the HDL cholesterol, total HDL particle, and large HDL particle concentrations. In contrast, DHEA replacement had no measurable effects on the lipoprotein particle profile in elderly men. Similarly, long-term physiological replacement of testosterone had no measurable effects on the lipoprotein particle profile in elderly men.
